Professional Documents
Culture Documents
ANSWER KEY:
2
JURISPRUDENCE
c. Abortive drugs
d. All of the above
11. It means a system of words or others system arbitrarily used to prevent words.
a. Code
b. Secret keys
c. Secrets clues
d. Cipher
12. Characteristics styles or symbols kept from the knowledge of others or disclosed confidentially to only one or
a few.
a. Code
b. Secret keys
c. Secrets clues
d. Cipher
13. An articles used for food or drink for man.
a. Device
b. Drug
c. Food
d. poison
14. Articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or
other animals.
a. Device
b. Drug
c. Cosmetics
d. Poison
15. Articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the
human body or any part thereof for cleaning, beautifying, promoting attractiveness, or altering the
appearance.
a. Device
b. Drug
c. Cosmetics
d. Poison
16. An instrument, apparatus, or contrivances, including their components, parts, and accessories, intended for
use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals.
a. Device
b. Drug
c. Food
d. Poison
17. A quality of any drug or device produced during a given cycle of manufacture.
a. Batch
b. Lot
c. Batch number
d. Lot number
18. The stated in the label of a drug or device after w/c the drug is not expected to retain its claimed safety,
efficacy, and quality or potency or after w/c it is not permissible to sell the drug or device.
a. Manufacturing date
b. Registration date
c. Production date
d. Expiration date
19. Drugs intended for use for animals.
a. Poison
b. Antibiotics
c. New drugs
d. New veterinary drugs
20. Any drug intended for use by man containing of any chemical substance w/c is produced by microorganism
and w/c has the capacity to inhibit or destroy microorganism in dilute solution.
2
JURISPRUDENCE
a. Poison
b. Antibiotics
c. New drugs
d. New veterinary drugs
21. Any ingredient intended for use in the manufacturing of drug including those that may not appear in the
finished product.
a. Component
b. Raw materials
c. New drug
d. None of the above
22. Any substance other than “active ingredient” present in a drug.
a. Raw material
b. Minute organism
c. Microorganism
d. Inactive ingredient
23. The concentration of known active drug substance in formulation.
a. Strength
b. Net content
c. Component
d. Stability
24. Articles (other than food) intended to affect the structure or any function of the body of man and recognized
in the Philippine National Formulary.
a. Medical plants
b. Brand name
c. Both a & b
d. Generic name
25. It refers to the proprietary name assigned to the product by the drug establishment.
a. Trade name
b. Brand name
c. Both a & b
d. Generic name
26. It refers to the identification of drugs and medicines by their scientifically and internationally recognized
active ingredient as determined by the BFAD of the Department of Health.
a. Trade name
b. Brand name
c. Both a & b
d. Generic name
27. Refers to the name/s and amount/s of active ingredients per dosage unit expressed in metric system.
a. Net content
b. Formulation
c. Strength
d. Potency
28. It refers to the classification of the product based on its therapeutic action as specified in the product
registration.
a. Pharmacologic category
b. Indication
c. Dosage form
d. Dosage formulation
29. It refers to the approved clinical use of the product based on substantial and scientifically supported
evidence of the safety and efficacy of the drug in the given dosage form.
a. Pharmacologic category
b. Indication
c. Dosage form
d. Dosage formulation
30. It is the pharmaceutical form of the preparation based on official pharmacopoeia.
2
JURISPRUDENCE
a. Pharmacologic category
b. Indication
c. Dosage form
d. Dosage formulation
31. It refers to the site and manner the product is to be introduced into or applied on the body.
a. Device
b. Direction for use
c. Mode of administration
d. Route of administration
32. It refers to the statements regarding the occurrence of potential hazards and side effects associated with the
use of the product and the limitations of its use.
a. Contraindications
b. Warning
c. Precautions
d. Indication
33. It refers to the statements regarding the condition wherein the use of the product may cause harm to the
patient.
a. Contraindications
b. Warning
c. Precautions
d. Indication
34. It refers to the instructions and special care required in the use of product to avoid undesired effects and to
ensure the safe and effective use of the drug.
a. Contraindications
b. Warning
c. Precautions
d. Indication
35. It refers to the total amount/ quantity/ number of the dosage form in a certain container of a product
expressed in metric system.
a. Volume
b. Strength
c. Net content
d. Potency
36. Refers to the part of the label that is most likely to be displayed, presented, shown or examined under
customary condition of display for retail use.
a. Principal display panel
b. Primary pack
c. Area of the principal display panel
d. Inserts
37. The first pack containing the individually wrapped products, strip, or blister packs.
a. Wrapper cartons
b. Inserts
c. Primary pack
d. Leaflets
38. Any establishment w/c is a registered owner of the drug product, procures the raw materials and packing
components, and provides the production monographs, quality control standards and procedures, but sub-
contracts the manufacturer of such product to a licensed manufacturer.
a. Drug Manufacturer
b. Drug trader
c. Drug Importer
d. Drug Exporter
39. The process of approval for the manufacture, importation, exportation, sale, offer for sale, distribution or
transfer of pharmaceutical products containing active ingredient/s of known chemical structure and
properties determined to be safe, efficacious, and of good quality according to standards of BFAD.
a. CGMP
2
JURISPRUDENCE
b. Registration
c. Assay
d. Drug Evaluation
40. A drug approved for sale to the general public under certain conditions.
a. Drug for Restricted Use
b. Drug for General Use
c. Drug for Limited Use
d. Drug for Registration
41. A drug which has been used for at least five years and involving at least 5,000 patients.
a. Investigational drugs
b. Established drugs
c. New drugs
d. Tried & tested drugs
42. It is a drug, the safety and efficacy of which has been demonstration through long years of general use and
can be found in the current official USP-NF, and other internationally recognized pharmacopeias.
a. Investigational drugs
b. Established drugs
c. New drugs
d. Tried & tested drugs
43. In Human Studies- Clinical Pharmacology Phase III.
a. Controlled Clinical Trials
b. Safety and Efficacy
c. Tolerance and Safety
d. Post marketing Surveillance
44. It is certification issued after a batch of antibiotics has been found to comply with the characteristics of
identity, strength, quality and purity.
a. Certification of Good Standing
b. Batch Certification
c. Certification of Product Registration
d. CGMP
45. It refers to standards and procedures whereby the laboratory achieves a defined, consistent and reliable
standard in performing laboratory tests and activities.
a. GMP
b. GCP
c. GLP
d. CPR
46. It is a document issued by the BFAD for the purpose of marketing, use or free distribution of a product in the
Philippines.
a. Certification of Good Standing
b. Batch Certification
c. CGMP
d. CPR
47. It refers to the standards and procedures for clinical trials that encompasses the design, protocol approval,
conduct, monitoring, termination, audit, analyses, reporting and documentation of human studies.
a. GMP
b. GCP
c. GLP
d. CPR
48. It means the label on or affixed to an immediate container.
a. Outer label
b. Inner label
c. Immediate label
d. Packaging display panel
49. It means a display of written, printed or graphic matter upon any article or any of its containers or wrappers
or attached to or accompanying such articles.
2
JURISPRUDENCE
2
JURISPRUDENCE
2
JURISPRUDENCE
69. Any person engaged in the business of selling consumer products directly to consumers.
a. Supplier
b. Exporter
c. Telemarketing
d. Retailer
70. It means a set of conditions to be fulfilled to ensure quality and safety of a product.
a. Standard
b. Services
c. Labor
d. None of the above
71. It includes rice, corn, bread, fish and drugs classified as essential by the department of health.
a. Basic necessities
b. Prime commodities
c. Primary needs
d. None of the above
72. It is contingent fund in the budget of the implementing agency w/c shall not be used in normal or regular
operation.
a. Petty cash
b. Buffer fund
c. Both a and b
d. Nota
73. It is the abnormal phenomenon where consumers buy basic necessities and prime commodities grossly in
excess of their normal requirement resulting in undue shortages of such goods to the prejudice of less
privileged consumers.
a. Hoarding
b. Panic buying
c. Cartel
d. Profiteering
74. It is the maximum price at which any basic necessities or prime commodities may be sold to the general
public.
a. Prevailing price
b. Price ceiling
c. Discounted price
d. 50% off of the original price
75. It is the undue accumulation by a person or combination of person of any basic necessity beyond his or their
normal inventory levels.
a. Hoarding
b. Panic buying
c. Cartel
d. Profiteering
76. The sale or offering for sale of any basic necessity or prime commodity at a price grossly in excess of its true
worth.
a. Hoarding
b. Panic buying
c. Cartel
d. Profiteering
77. It is any combination of or agreement between two or more persons engaged in the production,
manufacture, processing, storage, supply, distribution, marketing, sale or disposition of any basic necessity
or prime commodity design to artificially and unreasonably increased or manipulate its price.
a. Hoarding
b. Panic buying
c. Cartel
d. profiteering
78. An analytical test using a device, tool or equipment with a different chemical or physical principle that is
more specific which will validate and confirm the result of the screening test.
2
JURISPRUDENCE
a. Confirmatory test
b. Drug test
c. Drug analysis
d. None of the above
79. Any act of knowingly planting, growing, raising, or permitting the planning of any plant which is the source of
dangerous drugs.
a. Cultivate
b. Culture
c. Pusher
d. Both a and b
80. Any act of knowingly passing a dangerous drug to another, personally or otherwise, and by any means, with
or without consideration.
a. Cultivate
b. Deliver
c. Culture
d. Both a and c
81. The illegal cultivation, culture, delivery, administration, dispensation, manufacture, sale, trading,
transportation, distribution, importation, exportation and possession of any dangerous drugs and dangerous
drugs and/or controlled precursor and essential chemical.
a. Illegal trafficking
b. Illegal cultivation
c. Illegal selling
d. Illegal possession
82. Indian hemp.
a. Marijuana
b. Hashish
c. Bhang
d. All of the above
83. Ecstasy.
a. Methylenedioxymethamphetamine
b. Methyldioxymethamphetamine
c. MMCA
d. Methamphetamine Hydrochloride
84. Shabu.
a. Methylenedioxymethamphetamine
b. Methyldioxymethamphetamine
c. MMCA
d. Methamphetamine Hydrochloride
85. A rapid test performed to establish potential/ presumptive positive result.
a. Confirmatory test
b. Screening test
c. Test analysis
d. Laboratory test
86. Any person who is licensed physician, dentist, chemist, medical technologist, nurse, midwife, veterinarian or
pharmacist in the Philippines.
a. Practitioner
b. Coddler
c. Test analysis
d. Laboratory test
87. Any person, who sells, trades, administers, dispenses, delivers, or gives away to another, on any terms
whatsoever, or distributes, dispatches in transit or transport dangerous drugs or who act as a broker in any
such transactions.
a. Practitioner
b. Coddler
c. Protector
2
JURISPRUDENCE
d. Pusher
88. It is a license issued by the Director General of the Intellectual Property Office (IPO) to exploit a patented
invention without the permission of the patent holder, either by manufacture or through parallel importation.
a. Certificate of Product Registration
b. Compulsory license
c. Batch certificates
d. NOTA
89. It refers to drugstores, pharmacies, and other business establishment which sell drugs and medicines.
a. Drug Outlet
b. Drug Establishment
c. Drug laboratory
d. Both a and c
90. It refers to pharmaceutically equivalent or pharmaceutically alternative products that may or may not be
therapeutically.
a. Multisource pharmaceutical products
b. Multi-pharmaceutical products
c. Source pharmaceutical products
d. Pharmaceutical products
91. It refers to the international agreement administered by the WTO that sets down minimum standards for
many forms of intellectual property regulations.
a. TRIPS Agreement
b. WTO agreement
c. Agreement on Trade-Related Aspects of Intellectual Property Rights
d. Both a and c
92. Any change in law can be done by passing a/an.
a. Memorandum order
b. Amendments
c. Bill
d. Administrative order
93. If the entire batch of products is marketed under one company, only the lot number needs to be indicated.
a. The statement is incorrect
b. The statement is correct
c. Both the batch and the lot number should be indicated
d. Only the registration number is needed
94. The minimum age requirement to practice pharmacy in the Philippines.
a. 18
b. 19
c. 20
d. 21
95. The book kept for the purpose of recording the sale of violent poisons should be preserved for a period of.
a. 1 year
b. 2 years
c. 4 years
d. 5 years
96. Ordinary prescription shall be retained by the pharmacist for a period of.
a. 1 year
b. 2 years
c. 4 years
d. 5 years
97. Dangerous drug prescription shall be retained by the pharmacist for a period of.
a. 1 year
b. 2 years
c. 4 years
d. 5 years
98. The Rx symbol is required in the label of.
2
JURISPRUDENCE
a. Ethical drugs
b. Over the counter drugs
c. Prescription
d. Both a and c
99. Applicable S-tax for prescription of dangerous drugs.
a. S-1
b. S-2
c. S-3
d. S-4
100. Drug Registration of Herbal and/or Traditional Drugs (Local & Imported).
a. A.O. 63
b. A.O. 62
c. A.O. 42
d. A.O. 55
101. Revised Rules and Regulations to Implement Dispensing Requirement under the Generics Act of 1988.
a. A.O. 63
b. A.O. 62
c. A.O. 42
d. A.O. 55
102. Revised Rules and Regulations to Implement Prescribing Requirement under the Generics Act of 1988.
a. A.O. 63
b. A.O. 62
c. A.O. 42
d. A.O. 55
103. Amendment to A.O. 62.
a. A.O. 55
b. A.O. 90
c. A.O. 42
d. A.O. 56
104. Requirements for Labeling Materials of Pharmaceuticals Products.
a. A.O. 55
b. A.O. 90
c. A.O. 42
d. A.O. 56
105. Revised Regulations for Licensing of Drug Establishments and Oulets.
a. A.O. 42
b. A.O. 90
c. A.O. 64
d. A.O. 56
106. Amendments of A.O. 55.
a. A.O. 67
b. A.O. 90
c. A.O. 64
d. A.O. 56
107. Revised Rules and Regulation of Registration of Pharmaceutical Products.
a. A.O. 67
b. A.O. 90
c. A.O. 64
d. A.O. 56
108. The University Accessible Cheaper and Quality Medicines Act of 2008 is known as R.A.
a. 9257
b. 9502
c. 9165
d. 9205
109. The Comprehensive Dangerous Drug Act of 2002 known as R.A.
2
JURISPRUDENCE
a. 9257
b. 9502
c. 9165
d. 9205
110. The Expanded Senior Citizens Act of 2003 known as R.A.
a. 9257
b. 9502
c. 9165
d. 9205
111. The Pharmacy Law is known as R.A.
a. 5921
b. 6675
c. 3720
d. 8205
112. The Special Law on Counterfeit Drug is known as R.A.
a. 5921
b. 6675
c. 3720
d. 8203
113. The Generics Acts of 1988 is known as R.A.
a. 5921
b. 6675
c. 3720
d. 8203
114. The Foods, Drugs, Devices and Cosmetics Acts is knows as R.A.
a. 5921
b. 6675
c. 3720
d. 8203
115. The Price Act is Known as R.A.
a. 7432
b. 7581
c. 8293
d. 7394
116. The Consumers Act of the Philippines is known as R.A.
a. 7432
b. 7581
c. 8293
d. 7394
117. The Intellectual Property Code of the Philippines is known as R.A.
a. 7432
b. 7581
c. 8293
d. 7394
118. The Senior Citizens Act is known as R.A.
a. 7432
b. 7581
c. 8293
d. 7394
119. Filling and refilling of prescription shall be done by.
a. Intern with the supervision of the registered pharmacist
b. RPh
c. pharmacist
d. supervisor
2
JURISPRUDENCE
120. A certain drug is considered counterfeit if it contains less than how many percent of the active ingredient it
purports to possess?
a. 10
b. 40
c. 80
d. 95
121. The principal Display Panel comprises __% of the total surface of the container.
a. 10
b. 40
c. 80
d. 95
122. The test for alcohol content for registration of herbal and/or tradition drug should not be more than __%.
a. 10
b. 40
c. 80
d. 95
123. Amount of marijuana subject to life imprisonment to death and a fine ranging from 500,000 pesos to 10M
pesos.
a. 500 g
b. 10 g
c. 50 g
d. 40 g
124. Amount of shabu subject to life imprisonment to death and a fine ranging from 500,000 pesos to 10M pesos.
a. 500 g
b. 10 g
c. 50 g
d. 40 g
125. Amount of opium subject to life imprisonment to death and a fine ranging from 500,000 pesos to 10M pesos.
a. 500 g
b. 10 g
c. 50 g
d. 40 g
126. Amount of heroin subject to life imprisonment to death and a fine ranging from 500,000 pesos to 10M pesos.
a. 500 g
b. 10 g
c. 50 g
d. 40 g
127. The confiscated or seized dangerous drug, plant sources, controlled precursor and essential chemicals shall
be submitted to the PDEA Forensic Laboratory for a quantitative examination within.
a. 12 hour
b. 48 hour
c. 24 hour
d. 16 hour
128. If the seized drug was found to be counterfeit, the business establishment must be directed for preventive
closure for a period of.
a. 12 days
b. 15 days
c. 60 days
d. 30 days
129. Duration of the conduct of examination in determining the genuineness and authenticity of the product by the
bureau:
a. 10 working days
b. 20 working days
c. 16 working days
d. Within 24 hours
2
JURISPRUDENCE
130. The senior citizen shall be entitled the grant of ___discount for the consumption of electricity, water and
telephone by the senior citizens center and residential care/group homes that are non-stock, non-profit
domestic corporation:
a. 20%
b. 50%
c. 10%
d. 5%
131. The senior citizens shall be entitled the grant of ___ discount from all establishments relative to the
utilization of transportation services, restaurants and purchase of medicines anywhere in the country,
including funeral and burial services for the death of the senior citizens:
a. 20%
b. 50%
c. 10%
d. 5%
132. Re-application of the LTO after revocation may be done within ___ year/s:
a. 2
b. 3
c. 1
d. 5
133. The decision of the Board of Pharmacy in administrative cases involving a pharmacist becomes final and
executor after the lapses of:
a. 15 days
b. 60 days
c. 30 days
d. NMT 6 months from notice to respondents
134. Number of years of pharmacy practice for the pharmacist to qualify as board examiner:
a. 5 years
b. 10 years
c. 15 years
d. 20 years
135. R.A. 9165 was signed into law on:
a. June 7, 2002
b. February 26, 2004
c. June 23, 1969
d. June 23, 1963
136. R.A. 5921 was signed into law on:
a. June 7, 2002
b. February 26, 2004
c. June 23, 1969
d. June 23, 1963
137. R.A. 9257 was signed into law on:
a. June 7, 2002
b. February 26, 2004
c. June 23, 1969
d. June 23, 1963
138. R.A. 3730 was signed into law on:
a. June 7, 2002
b. February 26, 2004
c. June 23, 1969
d. June 22, 1963
139. R.A. 7394 was signed into law on :
a. April 13, 1992
b. February 26, 1992
c. February 7, 1992
d. September 13, 1988
2
JURISPRUDENCE
2
JURISPRUDENCE
2
JURISPRUDENCE
d. DOST
161. For products containing 3 or more active ingredients, the official name for the combination shall be
designated by:
a. DOST
b. DTI
c. DOH
d. BFAD
162. The potency of biological product must be expressed in :
a. Metric system
b. Apothecary
c. International unit
d. Avoirdupois
163. The word “single use” must be included in the label of :
a. Biological products
b. Small containers
c. Individually wrapped products
d. Large volume injection
164. The BFAD must be notified of such change in the establishment:
a. Change the manager
b. Change of pharmacist-in-charge
c. Change of product arrangement
d. Change of supervisor
165. The following must be displayed conspicuously inside the drug outlet:
a. Certificate of product registration
b. Diploma of the pharmacist-in-charge
c. Certificate of registration of the pharmacy
d. Certificate of registration of the pharmacist-in-charge
166. Basis for non-renewal of LTO of Drug Outlet and Drug Establishment:
a. Failure to comply with PRC standards and requirements
b. Serious repeated or rampant violation of existing laws, rules and regulation
c. Persistent performance that assures the safety, efficacy and quality of drug products
d. Poor housekeeping
167. Grounds for suspension of LTO of Drug Establishment:
a. Lapses in record keeping of invoices
b. Sales of antibiotics without batch certification
c. Selling of misbranded drug
d. Serious repeated or rampant violation of existing laws, rules and regulations
168. These are drugs found in the USP/NF and is considered safe and efficient through long years of general
use.
a. Investigational
b. Established
c. New
d. Tried and tested
169. Requirements for product registration, except:
a. Price
b. Brand identification
c. Prescribing and dispensing regulations applicable
d. Available scientific evidence
170. The source or circumstance of drug production is/are:
a. Imported as finished
b. Locally manufactured from local materials
c. Locally manufactured from imported materials
d. All of the above
171. Drug classification based on source:
a. Branded and patented
2
JURISPRUDENCE
b. Imported as finished
c. Unbranded and off patent
d. Both a and c
172. In a drug establishment, personnel responsible for directing the manufacture and control must:
a. Be inadequate in number
b. Graduate of any 4 year course
c. Have capabilities to commensurate with assigned function
d. Experience is not necessary
173. The amount of reserve sample of all ingredients to be kept for all required tests in the laboratory to be
performed are:
a. 5x
b. 3x
c. 2x
d. 4x of the quantity needed
174. Raw materials must not be accepted if there is:
a. Breakage of seal
b. Damage on the counter
c. Contamination in transit
d. All of the above
175. Registration of herbal and/or traditional drugs must be renewed every:
a. Year
b. 2 years
c. 3 years
d. 5years
176. Heavy metals to be tested in the herbal and/or traditional drugs except:
a. Hg
b. Pb
c. As
d. Cu
177. Requirements for registration of local herbal and/or traditional drugs :
a. Technical specification of the ingredients used as components
b. Government certificate of clearance
c. Free sale of drug
d. Certification of the importation of the drug
178. The discount privileges of the senior citizen shall be:
a. Transferable but limited sue only for the senior citizen
b. Non-transferable
c. Limited and exclusive for the benefits of the senior citizen
d. Both b and c
179. Violation of any provision of Senior Citizen Act is punishable by:
a. A fine not exceeding 2,000 pesos
b. Imprisonment of NLT 6 months but NMT 2 years for the first offense
c. Imprisonment not exceeding 2 months
d. A fine of 5,000 pesos but not exceeding 10,000 pesos
180. A drug product prescribed which is not registered at BFAD is considered a type of:
a. Impossible RX
b. Violate RX
c. Erroneous RX
d. Coded RX
181. The pharmacist received a prescription wherein the generic name does not correspond to the brand name,
the pharmacist:
a. Shall advise the prescriber of the problem
b. Must instruct the customer to get the proper prescription
c. Both a and b
d. May dispense of fill the said prescription
2
JURISPRUDENCE
2
JURISPRUDENCE
c. One subject
d. More than 4 subjects
193. The BOP, upon receipt of a formal complaint under oath against any pharmacist, shall furnish the latter copy
of the complaint which he shall answer within:
a. 30 days
b. 10 days
c. 60 days
d. 6 months from receipt
194. Any product that is not labeled in accordance with the requirements of A.O. 55 shall be deemed:
a. Misbranded
b. Conforms with the USP-NF standards
c. Both a and b
d. NOTA
195. The following are exempted from complying with the labeling requirements, except:
a. If the products are used solely for investigational use
b. If the products are compounded by the pharmacist
c. Established drugs
d. If the products are donated by foreign agencies
196. The BFAD shall be headed by a:
a. President
b. Secretary
c. Director
d. Commissioner
197. Any person desiring to operate or establish a drug establishment shall file with the BFAD an application
supported by the following documents, except:
a. Red & white labels indicating the name of the drugstore
b. Proof of registration
c. List of products to be manufactures identified by its generic and brand names
d. Current PTR of the pharmacist-in-charge
198. Any herbal and/or traditional drug the registration of which is not intended to be renewed may be given an
extension of NMT
a. 30 days
b. 10 days
c. 60 days
d. 6 months after the expiry date of such registration
199. Example of diagnostic reagents required to be registered:
a. Skin traction kit
b. Pregnancy test kits
c. Plaster bags for blood transfusion
d. blood
200. Example of a medical device required to be registered:
a. Skin traction kit
b. Pregnancy test kits
c. Plaster bags for blood transfusion
d. blood
201. Example of a product not required to be registered:
a. Skin traction kit
b. Pregnancy test kits
c. Plaster bags for blood transfusion
d. blood
202. Unless otherwise declared by the President, prices of the basic necessities in an area shall automatically be
frozen at their prevailing prices of placed under automatic price control whenever that area is:
2
JURISPRUDENCE
2
JURISPRUDENCE
b. RA 5921
c. RA 9165
d. RA 9502
213. An act providing for cheaper and quality medicines, amending for the purpose RA 8293, RA 6675, and RA
5921, and for other purposes:
a. RA 9165
b. RA 9257
c. RA 9502
d. RA 8485
214. An act to promote, require, and ensure the production of an adequate supply, distribution, use, and
acceptance of drugs and medicines identified by their generic names:
a. RA 3720
b. RA 6675
c. RA 9165
d. RA 9502
215. An act instituting the Comprehensive Dangerous Drugs Act of 2002, repealing RA 6425, as amended,
providing funds therefore, and for other purposes:
a. RA 3720
b. RA 6675
c. RA 9165
d. RA 9502
216. An act to ensure the safety & purity of foods & cosmetics, and the purity, safety, efficacy, and quality of
drugs and devices being made available to the publie, vesting the BFAD with authority to administer &
enforce the laws pertaining thereto, & for other purposes:
a. RA 3720
b. RA 6675
c. RA 9165
d. RA 9502
217. A candidate for Pharmacy board examination in the Philipines shall have the following qualification/sL
a. Natural-born Filipino citizen
b. Graduated with any four year course
c. Of good moral character
d. All of the above
218. What type of for was specified for printing the generic name if the name if the product is presented using a
special typeface exclusively designed for it?
a. Comic sans
b. Helvetica medium
c. Universe medium
d. Both b and c
219. Additional information for injections:
a. Recommended routes of administration
b. “Single use” or “Single dose”
c. Neither a nor b
d. Both a and b
220. In accordance to AO 56, s. 1989, the initial LTO has a validity of ___ years:
a. 5
b. 3
c. 2
d. 1
221. Under AO 56,s. 1989, the renewal of the LTO has a validity of ___ years:
a. 5
b. 3
c. 2
d. 1
2
JURISPRUDENCE
222. Under RA 9165, the penalty of 12 years and one day to 20 years of imprisonment and a fine of
100,000 pesos to 500,000 pesos shall be imposed upon any person who acts as a:
a. coddler
b.
c. protector
d. either a or c
223. -
a. -
b. -
c. -
d. -
224. -
a. -
b. -
c. Melting point
d. Dissolution
225. -
a. -
b. -
c. 222
d. 221
226. -
a. -
b. -
c. EO 175
d. EO 815
227. -
a. -
b. -
c. OSCA
d. PHILHEALTH
228. -
a. -
b. -
c. Any of the above
d. NOTA
229. -
a. -
b. -
c. Corazon C. Aquino
d. Ramon Magsaysay
230. CGMP means:
a. Current good manufacturing practice
b. Current good manufacturing process
c. Current good manufacture process
d. Current good manufacturing procedure
231. Which of the following is exempted in the labeling requirement?
a. Large volume injection
b. Product for external use
c. Products placed in small containers
d. Drugs for investigational purposes
232. Pharmacy Licensure Examination in the Philippines is held:
2
JURISPRUDENCE
a. Once a year
b. Twice a year
c. Every other year
d. Every December
233. Refusal to allow entry of BFAD inspector is penalized by:
a. Suspension of LTO
b. Revocation of LTO
c. Temporary closure
d. Cancellation of LTO
234. It is composed of a core list of medicines considered essential and a complimentary list of drugs considered
useful if not essential:
a. MIMS
b. PDR
c. Goodman & Gilman
d. Natianal Drug Formulary (NDF)
235. Monitors the treatment and rehabilitation of drug dependents and operation of drug rehabilitation and testing
centers:
a. PDEA
b. BFAD
c. NBI
d. DOH
236. Define as the delivery or sale of any drug or device for purposes of distribution in commerce, except that
such term does not include a manufacturer or retailer of such product.
a. Import
b. Distribute
c. Export
d. Manufacture
237. Quality control requirements for herbal and/or traditional drugs:
a. Test for the presence of heavy metals
b. Test for the presence of synthetic drugs
c. Test for alcohol content
d. All of the above
238. Pursuant to AO 55, all information required to appear on the label must be:
a. Written in english
b. Clearly and prominently displayed
c. Readable with normal vision with straining
d. All of the above
239. INN means:
a. International Non-Proprietary Name
b. International Proprietary Name
c. International Non-Proprietary
d. International Name
240. Based on the PNDF, the following are acting on the CNS except:
a. Anti-gout
b. Anti-schistosoma
c. Anti-parkinsonism
d. Anti-vertigo
241. Based on the PNDF, the following are Gastro-Intestinal drugs, except:
a. Anti-lipidemic
b. Anti-cholinergic
c. Spasmolytic
d. Antacid
242. The division in BFAD that evaluates and processes application for the registration of all products under
BFAD’s jurisdiction:
a. LSD
2
JURISPRUDENCE
b. PSD
c. LICD
d. Regulation Division II
243. The division in BFAD that conducts all test analyses and trials of products under BFAD’s jurisdiction:
a. LSD
b. PSD
c. LICD
d. Regulation Division II
244. The division in BFAD that conducts administrative or quasi-judical hearings and recommends, imposes
appropriate legal action:
a. LSD
b. PSD
c. LICD
d. Regulation Division II
245. The division in BFAD that calls upon erring manufacturer, distributor, or advertiser to desist from inaccurate
or misleading nutritional or medical claims in their advertising:
a. LSD
b. PSD
c. LICD
d. Regulation Division II
246. It refers to the prevailing specified range of temperature, humidity, and other environment factors within
optimal stability of the product:
a. Storage conditions
b. Temperature range
c. Stability
d. Expiry date
247. The expiry date of the product shall be expressed in terms of the:
a. Month and year
b. Month, date, & year
c. Year
d. Date and year
248. PRC means:
a. Philippine Regulation Commission
b. Professional Regulatory Commission
c. Philippine Regulatory Commission
d. Professional Regulation Commission
249. Requirement/s for registration of “Me-Too” or identical products includes:
a. Toxicology data
b. Pharmaceutical form of the drug
c. Clinical evaluation data
d. Mutagenicity
250. It is the current system of quality assurance aimed at ensuring that products are consistently manufactured
to a quality appropriate for intended use:
a. GLP
b. GCP
c. CGMP
d. CPL
251. Example/s of Cosmetic Specialty Qualified for Listing without Pre-Market Approval:
a. Lipsticks
b. After shave lotion
c. Perfumes
d. AOTA
252. President Corazon C. Aquino enunciated the National Drug Policy on:
a. May 30, 1987
b. April 30, 1987
2
JURISPRUDENCE
2
JURISPRUDENCE
a. PRC
b. BFAD
c. PPhA
d. DDB
264. Acts as the policy formulation and sector monitoring arm of the Secretary of Health on matters pertaining to
foods, traditional medicines, cosmetics, and household products containing hazardous substances:
a. Director of PDEA
b. DDB Director
c. BFAD Director
d. President of PPhA
265. Collects samples of products in outlets under BFAD jurisdiction for laboratory analysis:
a. Regulation Division I
b. Regulation Division II
c. LSD
d. LICD
266. Assist in the development of the short/long range plan and prepares the budget estimates of BFAD:
a. Office of the director
b. LICD
c. Administrative Division
d. Regulation Division II
267. Coordinates the activities of the Drug Information Unit (DIU) for the purposes of information dissemination:
a. Office of the Director
b. Administrative Division
c. LICD
d. Regulation Division II
268. It is an act providing protection to consumers by stabilizing the prices of basic necessities & prime
commodities and by prescribing measures against undue price increases during emergency situations and
like occasions:
a. RA 7394
b. RA 7581
c. RA 7432
d. RA 3720
269. This order prescribes the conditions and requirements for good manufacturing practice applied to premises,
equipment, personnel, product and warehouse:
a. AO 220
b. AO 42
c. AO 56
d. AO 67
270. This order defines rules and regulations governing the registration and sale of herbal and/or traditional drugs
to ensure their quality and safety:
a. AO 220
b. AO 42
c. AO 56
d. AO 67
271. This order prescribes the activities involving drug products that need to be covered by a licensed from
BFAD:
a. AO 220
b. AO 42
c. AO 56
d. AO 67
272. This order gives comprehensive guidelines on the registration of pharmaceutical products to be consistent
with RA 6675:
a. AO 220
b. AO 42
c. AO 56
2
JURISPRUDENCE
d. AO 67
273. Laboratory controls are required for:
a. Finished products
b. components
c. In-process drug
d. All of the above
274. Ointments, creams, and other semi-solid preparations are tested for:
a. Melting point
b. Homogeneity
c. Impalpability
d. All of the above
275. Equipment used for manufacturing, processing, packing, labeling, testing and control of drugs must be:
a. Of suitable size
b. Absorptive
c. Impalpability
d. Both a and c
276. What is the color of the label for prescriptions used externally?
a. Pink
b. Red
c. Green
d. White
277. This is a proof that a person is a licensed pharmacist:
a. Certificate of registration
b. Transcript of record
c. Certificate of internship
d. All of the above
278. As defined in RA 8203, this refers to any entity, whether a single proprietorship, partnership, or corporation
engaged in or doing business in the Philippines:
a. residency
b. business establishment
c. brokering
d. ownership
279. Under RA 5921, administrative investigation shall be conducted by all members of the Board of pharmacy.
In case of suspension, it shall be for a period of NMT:
a. 1 year
b. 30 days
c. 6 months
d. 60 days
280. Which of the following statements is/are true for detailman?
a. An initial fee of twenty pesos is needed upon registration
b. He shall be, preferably a graduate of a College of Pharmacy
c. To be employed, he needs to possess the necessary credentials issued by the PRC.
d. Only a and b.
281. For how many years shall the Chairman and members of the Board of Pharmacy hold office after
appointment?
a. 2
b. 3
c. 4
d. 5
282. Under RA 3720, if a drug’s strength differs or its safety, efficacy, quality or purity falls below the standards
set forth in the compendium, then the drug is deemed to be.
a. Adulterated
b. Mislabeled
c. Ineffective
d. All of the above
2
JURISPRUDENCE
283. In order to manufacture, sell, offer for sale, import or distributed any drug or device, a license to operate
should be first secured from.
a. BFAD
b. DTI
c. PRC
d. DDB
284. Any person who shall be employed as detailmen by any pharmaceutical established shall be first secured
from.
a. BFAD
b. DTI
c. PRC
d. DDB
285. If found guilty of neglect of duty, incompetence, malpractice, unprofessional or dishonorable conduct, after
having been given been the opportunity to defend himself in a administrative, the chairman or members of
the Board of Pharmacy may be removed by.
a. President of PACOP
b. President of the Philippines
c. PRC Commissioner
d. Director of BFAD
286. R.A. 3720 was amended by EO no ____?
a. 851
b. 174
c. 175
d. 881
287. A certified true copy of the record of dangerous must be submitted to.
a. DDB
b. PDEA
c. 175
d. DOH
288. This refers to any facility used for the illegal manufacture of any dangerous drug/or controlled precursors
and essential chemical.
a. classrooms
b. clandestine laboratory
c. licensed establishment
d. all of the above
289. Maximum penalty shall be imposed if the sale, trading, administration, delivery or distribution of dangerous
drugs and/ or controlled precursor and essential chemicals transpires within __ meters from school.
a. 50
b. 100
c. 101
d. 30
290. Penalty for unlawful prescription of dangerous drugs.
a. Fine of Php 100,000 to 50,000
b. Life imprisonment to death
c. Fine of Php 500,000 to 10 M
d. b and c
291. The term “elderly” shall mean:
a. Senior citizen
b. Any resident of the Philippines
c. At least 60 years old
d. All of the above
292. The term Secretary, in RA 3720, means:
a. Secretary of DOH
b. Secretary of the DTI
c. Secretary of Education
2
JURISPRUDENCE